-
Posted by
Two Blokes May 28, 2025 -
Filed in
Stock
-
10 views
uniQure recently divested from its Lexington facility to Genezen and freed $25 million while significantly reducing its operating costs. At the same time, AMT-130 has received the FDA's Breakthrough Therapy, RMAT, Fast-Track, and Orphan Drug status with Accelerated Approval via cUHDRS. Similarly, QURE is building MRI-guided infusion centers, payer-access teams, and a US Center of Excellence network. All of these moves prove management's high confidence in AMT-130.
